|
|
|
|
LEADER |
01918nam a22004095i 4500 |
001 |
000282088 |
005 |
20211101082258.0 |
007 |
cr nn 008mamaa |
008 |
100301s2007 sz | s |||| 0|eng d |
020 |
|
|
|a 9783764377830
|
024 |
7 |
|
|a 10.1007/978-3-7643-7783-0
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Entry Inhibitors in HIV Therapy /
|c edited by Jacqueline D. Reeves, Cynthia A. Derdeyn.
|
250 |
|
|
|a 1st ed. 2007.
|
260 |
# |
# |
|a Basel :
|b Birkhäuser Basel :
|b Imprint: Birkhäuser,
|c 2007.
|
300 |
|
|
|a X, 206 p. :
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Milestones in Drug Therapy,
|
505 |
0 |
|
|a to entry inhibitors in the management of HIV infection -- The challenge of HIV sequence diversity in the envelope glycoprotein -- Attachment of human immunodeficiency virus to cells and its inhibition -- Inhibitors that target gp120-CD4 interactions -- Inhibitors that target gp120 interactions with coreceptor -- Inhibitors that target fusion -- HIV-1 entry inhibitors as microbicides -- Entry inhibition of HIV-1 subtype C isolates -- The utility of coreceptor typing in the clinic -- Future clinical prospects for entry inhibitors -- Enfuvirtide: from basic science to FDA approval -- Targets for drug development — past and present.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
|
0 |
|a Immunology.
|
650 |
|
0 |
|a Virology.
|
650 |
|
0 |
|a Infectious diseases.
|
650 |
|
0 |
|a Pathology.
|
650 |
|
0 |
|a Cell biology.
|
650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
650 |
2 |
4 |
|a Immunology.
|
650 |
2 |
4 |
|a Virology.
|
650 |
2 |
4 |
|a Infectious Diseases.
|
650 |
2 |
4 |
|a Pathology.
|
650 |
2 |
4 |
|a Cell Biology.
|
700 |
1 |
|
|a Reeves, Jacqueline D.
|e editor.
|
700 |
1 |
|
|a Derdeyn, Cynthia A.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|